Thyroid cancer: burden of illness and management of disease - Wikidata - wikimedia - TriplyDB

Thyroid cancer: burden of illness and management of disease

Thyroid cancer: burden of illness and management of disease

http://www.wikidata.org/entity/Q34821078

about

Progress in molecular-based management of differentiated thyroid cancer BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence Flavonoids, Thyroid Iodide Uptake and Thyroid Cancer-A Review.Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways.The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer.Cost-of-Illness Trend of Thyroid Gland Disease in Korea.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.Protocol of a thyroid cancer longitudinal study (T-CALOS): a prospective, clinical and epidemiological study in Korea Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF Association of CFTR gene polymorphisms with papillary thyroid cancer.Concurrent hyperthyroidism and papillary thyroid cancer: a fortuitous and ambiguous case report from a resource-poor setting.Drosophila Cancer Models Identify Functional Differences between Ret Fusions.Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.Relationship between negative mental adjustment to cancer and distress in thyroid cancer patients Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.Differentiated thyroid tumors: surgical indications.High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.Thyroid Disease and Surgery in CHEER: The Nation's Otolaryngology-Head and Neck Surgery Practice-Based Network.Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer.Prognostic biomarkers in thyroid cancer.Genomic medicine for cancer prognosis.Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies.miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.Expression and clinical significance of connective tissue growth factor in thyroid carcinomas.Structural alterations in tumor-draining lymph nodes before papillary thyroid carcinoma metastasis.Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.Comprehensive analysis of long noncoding RNA-mRNA co-expression patterns in thyroid cancer.Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry.BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.MiR-135a-5p modulates biological functions of thyroid carcinoma cells via targeting VCAN 3'-UTR.Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma.Downregulation of BANCR Promotes Aggressiveness in Papillary Thyroid Cancer via the MAPK and PI3K Pathways.Navigation programs, are they helpful for perioperative care with thyroid cancer patients?miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10 Evaluation of the Role of V600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition Wnt/β-Catenin Pathway

P2860

Q26999887-680F37EC-3469-48D6-9F5F-F471664B8EB2 Q27853042-9E06466F-91E2-4E53-AC60-0E1448C48C6F Q33838859-2161B5CB-7E72-40BC-AD02-9F96236FFB26 Q33909333-5863CE9E-C114-476B-812E-12AA43CF9B55 Q33973118-CAB4E6B4-B321-4840-83A4-34044F104D23 Q34174513-D4E20E8D-342B-4EE6-B3C8-F14CDA4756DD Q34318805-1C44F526-D5C7-47F3-BC17-416A3CE4CAC7 Q34716574-80CFF9B0-30FE-42B9-9496-FF8D6A5D6470 Q34903411-BB1A417B-53D5-4E72-BFA9-CD7119517D06 Q35914464-C4A591A5-AACB-43C1-84B9-BE0FFACFDFDB Q35995455-F86F2C3C-DC9B-4537-9170-C2EEA4574A9C Q36086754-EA01975C-E136-4B3A-9AE8-E560BDE1038B Q36132331-9BA22527-8277-4F17-963A-080D9EECECF4 Q36217960-25C03389-89E8-476B-BC4A-7C18BA5AB3F4 Q36793102-66071E38-034A-4359-B9EB-A56A9CA4F119 Q37216703-6CDDBBC3-211B-49B8-A8C4-FBA37A1BACC7 Q37560570-23D6B97B-0D32-4F61-8EEF-66C32E4D645D Q37569299-710E9D50-5AA7-4870-8A00-D5B97B350652 Q37643436-991C0BD0-D45B-4019-9191-6C72E409EB03 Q38086706-43BBBBE5-728E-423A-B5BF-D0A4C232D9F1 Q38184374-28BC96B8-B0EE-43B6-A838-2AFCDA01DDA4 Q38238835-6632711E-D9F7-4A4F-98E4-54E3C1AE4F7E Q38721735-AF492809-1856-4653-9F3E-46E6BB3B4ADB Q38826614-2F6D9657-625A-4429-A1FC-50F8FC3BED47 Q41180944-27FE28E9-E2F5-4BDA-A867-8E26811C1476 Q44734130-85639E2F-E066-4D27-A87F-AAEBB6085A53 Q47149651-384700C4-6399-45B7-A8E9-79D5EDEF0110 Q47702648-601DA78E-6685-49F2-A845-BEE91362F3C5 Q47941020-65E19C53-F218-4533-84A4-727F6525EA74 Q47976968-089DC707-4D48-448D-B80E-9D69951E51EC Q48348571-233DFA41-8C67-4893-9FAF-17A2DF5B17F1 Q49808093-32B995BC-8648-4AE8-9EBB-68D1F3C97706 Q50225576-7638EF8A-0BBB-4B21-8E6B-392CB33B3D5B Q50982413-9D5262FC-F9A9-43DF-B50D-1AB24E88B691 Q52576028-689A8173-2270-46C5-B850-AC39DFB43998 Q53137718-1A2876CA-3AA7-4A9E-917D-A1D7D5AA05E0 Q57068280-13FFD091-FC1E-4057-8615-D7C26A37CC12 Q58124607-A40B1A0E-C796-410B-8F7F-BE0756A98144 Q58573121-F160264B-FB0F-47A8-ACE6-5A2B146CB612 Q58778664-4E061128-8D99-4B62-B2C8-3805C4115616

P2860

Thyroid cancer: burden of illness and management of disease

http://www.wikidata.org/entity/Q34821078

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Thyroid cancer: burden of illness and management of disease

@ast

Thyroid cancer: burden of illness and management of disease

@en

Thyroid cancer: burden of illness and management of disease

@nl

type

label

Thyroid cancer: burden of illness and management of disease

@ast

Thyroid cancer: burden of illness and management of disease

@en

Thyroid cancer: burden of illness and management of disease

@nl

prefLabel

Thyroid cancer: burden of illness and management of disease

@ast

Thyroid cancer: burden of illness and management of disease

@en

Thyroid cancer: burden of illness and management of disease

@nl

P1433

Q34821078-3B6B90A4-2A71-4054-8E24-44793286A345

P1476

Q34821078-067AB803-C722-4B52-A1B0-473F5FB966DE

P2093

Q34821078-5F0DFDDC-224E-40F9-B96E-705E9F16323E

Q34821078-B114587E-DD4B-4253-ADB6-BA3AAEA438C8

Q34821078-DCAF96FC-E69E-452C-8B07-FA357B981779

P2860

Q34821078-170E41F7-9C13-4EDB-98D5-E21BE8EA948B

Q34821078-21CB43E8-F0B2-4844-AFCF-C34F42AF1388

Q34821078-252924A9-844C-4D6F-BBB2-E959AEB04874

Q34821078-27417815-10AA-463F-8F4F-41DFCAE93DBC

Q34821078-3528B092-DBF7-4CCA-872E-C61C4B281203

Q34821078-557CB4E3-9806-492D-9957-E8C8A8661FE5

Q34821078-5B964F43-7241-4930-9BFB-3C3768C223C7

Q34821078-5CDDF9B7-31F8-4E42-AE2C-DCFD5BADAD20

Q34821078-64C7F4C0-AF31-437B-B58A-A2E183C53C10

Q34821078-7BE286CF-DC95-4746-9D21-CCB0995720EE

P304

Q34821078-A60B85EA-0057-4754-BF32-EA8FF4F70E14

P31

Q34821078-47E8D522-CEED-4EE8-B138-35B1BC907D9A

P356

Q34821078-EB1F1E3B-D6AD-489E-94A5-37D15FB51187

P478

Q34821078-23AE921B-63AA-441A-BE2F-102D92B84CC6

P577

Q34821078-E546C490-7364-4FF1-9971-5DCF82FF4788

P698

Q34821078-66DAA06B-791D-425B-83BF-69F1CF762793

P932

Q34821078-3F016876-827B-41A8-B832-C4F26F6CC925

P356

P1433

Journal of Cancer

P1476

Thyroid cancer: burden of illness and management of disease

@en

P2093

Ezra Ew Cohen

http://www.w3.org/2001/XMLSchema#string

Jonas A de Souza

http://www.w3.org/2001/XMLSchema#string

Rebecca L Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Motesanib diphosphate in progressive differentiated thyroid cancer.

Epidemiology of thyroid nodules.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Thyroid-hormone therapy and thyroid cancer: a reassessment.

Total thyroidectomy for differentiated thyroid cancer.

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Phase II trial of sorafenib in metastatic thyroid cancer

P304

193-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.2.193

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21509149

http://www.w3.org/2001/XMLSchema#string

P932

3079916

http://www.w3.org/2001/XMLSchema#string